These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7983237)

  • 21. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
    Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T
    Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350
    [No Abstract]   [Full Text] [Related]  

  • 22. [Antigenicity studies of prulifloxacin (NM441)].
    Tateda C; Sakai K; Yamakawa S; Nakasuji T; Nakamura T; Sumi N; Shindo Y
    J Toxicol Sci; 1996 Jun; 21 Suppl 1():231-9. PubMed ID: 8709164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and safety of single oral doses of lomefloxacin.
    Morse IS
    Biopharm Drug Dispos; 1990; 11(6):543-51. PubMed ID: 2207304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects.
    Stass H; Dalhoff A; Kubitza D; Schühly U
    Antimicrob Agents Chemother; 1998 Aug; 42(8):2060-5. PubMed ID: 9687407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of prulifloxacin on infectious enteritis. Japan Research Committee of Prulifloxacin, Research Group on Infectious Enteritis].
    Tomizawa I; Takizawa Y; Nitta Y; Tsunoda T; Fukuda H; Yamaguchi T; Masuda G; Negishi M; Ajisawa A; Murata M; Ohnishi K; Irimajiri S; Obana M; Sajima Y; Sagara H; Kato H; Hosoda S; Banba T; Sasaki M; Yoshikawa K; Nakagawa M; Ohkubo H; Kim Y; Akao M; Fukuyama M
    Kansenshogaku Zasshi; 1996 Jul; 70(7):727-45. PubMed ID: 8797308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of grepafloxacin.
    Efthymiopoulos C
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():35-43. PubMed ID: 9484872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.
    Mattina R; Bonfiglio G; Cocuzza CE; Gulisano G; Cesana M; Imbimbo BP
    Chemotherapy; 1991; 37(6):389-97. PubMed ID: 1662127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A 4-week oral toxicity study of prulifloxacin (NM441) in rats followed by a 4-week recovery test].
    Nishimura N; Fukuda K; Yamazaki S; Tamura K; Shindo Y; Iwakura K; Sumi N
    J Toxicol Sci; 1996 Jun; 21 Suppl 1():45-70. PubMed ID: 8709169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro antibacterial activity of prulifloxacin, a new oral fluoroquinolone].
    Araake M; Hara T; Watabe H; Nishino T
    Jpn J Antibiot; 2002 Dec; 55(6):778-90. PubMed ID: 12621732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Single and 4-week oral toxicity studies of prulifloxacin (NM441) in aged dogs].
    Ihara T; Akune A; Nakama K; Chihaya Y; Nagata R; Sumi N; Asaoka H; Shindo Y
    J Toxicol Sci; 1996 Jun; 21 Suppl 1():149-69. PubMed ID: 8709158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prulifloxacin. NAD-441A, NM 441, Quisnon.
    Drugs R D; 2002; 3(6):426-30. PubMed ID: 12516950
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics and urinary excretion of DW116, a new fluoroquinolone antibacterial agent, in humans as a phase I study.
    Jung BH; Choi MH; Chung BC
    Drug Dev Ind Pharm; 2000 Jan; 26(1):103-6. PubMed ID: 10677817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and tolerance of a new fluoroquinolone antimicrobial drug after single oral doses in healthy volunteers.
    Tanaka M; Tamura K; Atarashi S; Kubo Y; Oliver SD; Bentley M; Hakusui H
    Xenobiotica; 1995 Nov; 25(10):1119-25. PubMed ID: 8578768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.
    Kisicki JC; Griess RS; Ott CL; Cohen GM; McCormack RJ; Troetel WM; Imbimbo BP
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1296-301. PubMed ID: 1329618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of age and gender on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():9-17. PubMed ID: 9433651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.
    Mallikaarjun S; Salazar DE; Bramer SL
    J Clin Pharmacol; 2004 Feb; 44(2):179-87. PubMed ID: 14747427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and tolerance of lomefloxacin after sequentially increasing oral doses.
    Morrison PJ; Mant TG; Norman GT; Robinson J; Kunka RL
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1503-7. PubMed ID: 3214495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.
    Wise R; Johnson J; O'Sullivan N; Andrews JM; Imbimbo BP
    J Antimicrob Chemother; 1991 Dec; 28(6):905-9. PubMed ID: 1667783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg.
    Montay G; Bruno R; Vergniol JC; Ebmeier M; Le Roux Y; Guimart C; Frydman A; Chassard D; Thebault JJ
    J Clin Pharmacol; 1994 Nov; 34(11):1071-6. PubMed ID: 7876398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inhibitory activity of NM394, the active form of prodrug prulifloxacin against type II topoisomerase from Pseudomonas aeruginosa].
    Tani M; Maebashi K; Araake M; Watabe H
    Jpn J Antibiot; 2002 Dec; 55(6):882-5. PubMed ID: 12621742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.